Category Archives: multiple sclerosis (MS)

Gilenya fingolimod Drug Safety Communication

Share

Gilenya (fingolimod) – Drug Safety Communication: Investigating Rare Brain Infection AUDIENCE: Neurology, Pharmacy ISSUE: FDA is alerting the public that a patient in Europe diagnosed with possible multiple sclerosis (MS) has developed a rare and serious brain infection after taking … Continue reading

Share
Posted in FDA 2013, FDA Notice, multiple sclerosis (MS), Neurology, Pharmacy | Tagged , , , , , , , , , , , , , | Comments Off on Gilenya fingolimod Drug Safety Communication

Gilenya (fingolimod) Drug Safety Communication

Share

Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose AUDIENCE: Neurology, Patients ISSUE: The FDA has received a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking … Continue reading

Share
Posted in FDA 2011, FDA Notice, multiple sclerosis (MS), Neurology | Tagged , , , , , | Comments Off on Gilenya (fingolimod) Drug Safety Communication